Novartis Lines Up $1 Billion For China R&D
This article was originally published in The Pink Sheet Daily
In-country research staff will increase over six-fold to approximately 1,000.
You may also be interested in...
China's pharma companies may one day soon find themselves without the R&D support of the country's leading universities, and companies have the country's push to improve IP protection to thank
SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences
SHANGHAI - Swiss drug maker Novartis plans to deepen its investment in China this year despite the West's economic downturn, and will expand its research and development center here while launching new drugs in the Chinese market, according to high-level Novartis executives